Toronto Hospital
Welcome,         Profile    Billing    Logout  
 2 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wong, David
NCT05372419: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color

Active, not recruiting
3
80
US
Lebrikizumab, LY3650150, DRM06
Eli Lilly and Company
Atopic Dermatitis
05/24
02/25
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
NCT03692897: An Observational Study of Patients With Chronic Hepatitis B (CHB) Infection

Recruiting
N/A
5000
Canada, US
All approved therapies for the treatment of Chronic Hepatitis B (CHB)
Target PharmaSolutions, Inc.
Hepatitis B, Hepatitis, Liver Diseases
01/26
01/26

Download Options